HUE065746T2 - Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére - Google Patents

Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Info

Publication number
HUE065746T2
HUE065746T2 HUE13836324A HUE13836324A HUE065746T2 HU E065746 T2 HUE065746 T2 HU E065746T2 HU E13836324 A HUE13836324 A HU E13836324A HU E13836324 A HUE13836324 A HU E13836324A HU E065746 T2 HUE065746 T2 HU E065746T2
Authority
HU
Hungary
Prior art keywords
preparations
treatment
methods
mycobacterium tuberculosis
tuberculosis infection
Prior art date
Application number
HUE13836324A
Other languages
English (en)
Hungarian (hu)
Inventor
Steven Reed
Rhea Coler
Original Assignee
Access To Advanced Health Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access To Advanced Health Inst filed Critical Access To Advanced Health Inst
Publication of HUE065746T2 publication Critical patent/HUE065746T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13836324A 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére HUE065746T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679612P 2012-08-03 2012-08-03
US201361791213P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE065746T2 true HUE065746T2 (hu) 2024-06-28

Family

ID=50278593

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13836324A HUE065746T2 (hu) 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Country Status (13)

Country Link
US (2) US20150182612A1 (https=)
EP (2) EP2879701B1 (https=)
JP (1) JP2015525784A (https=)
CN (1) CN104812404A (https=)
BR (1) BR112015002483A2 (https=)
ES (1) ES2969734T3 (https=)
HR (1) HRP20240164T1 (https=)
HU (1) HUE065746T2 (https=)
MX (1) MX385774B (https=)
PT (1) PT2879701T (https=)
RU (1) RU2659149C2 (https=)
WO (1) WO2014042780A1 (https=)
ZA (2) ZA201501242B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190009308A (ko) * 2016-05-21 2019-01-28 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 2차 결핵 및 비결핵성 마이코박테리아 감염을 치료하기 위한 조성물 및 방법
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
KR20240096468A (ko) 2021-09-22 2024-06-26 에이치디티 바이오 코포레이션 감염병에 대한 rna 백신

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
RU2262950C2 (ru) * 2001-03-23 2005-10-27 Каунсил Оф Сайентифик Энд Индастриал Рисерч Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
EP2426141B1 (en) * 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
EP1991213A2 (en) * 2006-02-08 2008-11-19 Fasgen, Inc. Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
PT2468300T (pt) 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
ES2621211T3 (es) * 2007-04-04 2017-07-03 Infectious Disease Research Institute Composiciones inmunogénicas que comprenden polipéptidos de mycobacterium tuberculosis y fusiones de los mismos
WO2010010178A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
CA2732750A1 (en) * 2008-09-22 2010-03-25 The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs Methods for detecting a mycobacterium tuberculosis infection
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EP2618838A1 (en) * 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis

Also Published As

Publication number Publication date
RU2015107435A (ru) 2016-09-27
US11369672B2 (en) 2022-06-28
ES2969734T3 (es) 2024-05-22
EP2879701A4 (en) 2016-01-20
EP4299138A3 (en) 2024-08-14
US20200038498A1 (en) 2020-02-06
MX385774B (es) 2025-03-18
US20150182612A1 (en) 2015-07-02
EP2879701A1 (en) 2015-06-10
HRP20240164T1 (hr) 2024-04-12
EP2879701B1 (en) 2023-11-15
ZA201501242B (en) 2017-08-30
RU2659149C2 (ru) 2018-06-28
EP4299138A2 (en) 2024-01-03
ZA201702091B (en) 2018-12-19
JP2015525784A (ja) 2015-09-07
BR112015002483A2 (pt) 2017-11-07
CN104812404A (zh) 2015-07-29
PT2879701T (pt) 2024-02-12
MX2015001557A (es) 2015-10-08
WO2014042780A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
IL284506B (en) Biological markers and signatures for diagnosing infections and methods for their use
HUE065746T2 (hu) Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
IL251647A0 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
IL283432A (en) Compositions, methods and systems for the treatment of cutaneous disorders
HUE058731T2 (hu) Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
HUE047782T2 (hu) Gyógyászatilag aktív vegyületek és alkalmazási eljárásaik
HUE046292T2 (hu) Melanóma kezelése és diagnosztizálása
ZA201408119B (en) Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
HUE036561T2 (hu) Készítmények rheumatoid arthritis kezelésére és eljárások alkalmazására
IL244089A0 (en) Diagnostic methods and compositions for treatment of glioblastoma
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
HUE044778T2 (hu) Humán RPE sejt gyógyászati készítmények és alkalmazásaik
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
EP2800590C0 (en) SLOTTED AND SIDE-OPENING CATHETER DEVICES
IL235130A0 (en) Compositions for topical treatment of microbial infections
HUE046963T2 (hu) Készítmények és kezelés szembetegségekhez és rendellenességekhez
HUE036930T2 (hu) Készítmények és eljárások MASP-1 és/vagy MASP-3 gátlására paroxymalis nocturnalis hemoglobinürítés kezelésére
IL237760B (en) Acylaminopyrimidine history for the treatment of viral infections and other diseases
IL237173A0 (en) Methods for treating hepatitis b and hepatitis d infections
HUE044816T2 (hu) Készítmények és eljárások hajhullás kezelésére
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
IL234606B (en) Novel methods and composition for treatment of disease
IL244881B (en) Hiv treatment formulation of atazanavir and cobicistat